Efgartigimod for Guillain-Barré syndrome: a retrospective analysis of efficacy and safety - PubMed
4 days ago
- #immunotherapy
- #Guillain-Barré syndrome
- #efgartigimod
- Efgartigimod evaluated for Guillain-Barré syndrome (GBS) in a retrospective study of 36 patients.
- Significant clinical improvement observed in both first-line and escalation therapy groups over 8 weeks.
- First-line therapy showed faster initial response and shorter time to favorable outcome (6 vs 25 days).
- Greater baseline severity and need for mechanical ventilation associated with longer recovery time.
- Exploratory analysis suggested immunomodulatory effects with decrease in certain T cell subsets.
- Only two mild adverse events reported, indicating a favorable safety profile.
- Supports further prospective evaluation of efgartigimod for GBS treatment.